At the news
? NEUTRALIMPACT 3/10 8-K filed Nov 12, 2026 at 16:10 ET
Fulcrum Therapeutics entered into an asset purchase agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third party for approximately $7.0 million in cash. The sale is contingent on the closing of Fulcrum's proposed merger with Slate Medicines, and proceeds will be escrowed and credited to Fulcrum's net cash, potentially increasing the cash dividend expected in connection with the merger.
- On November 7, 2026, Fulcrum and Slate entered into an asset purchase agreement for the sale of early-stage HbF assets.
- The sale price is approximately $7.0 million in cash.
- Closing is contingent on consummation of the proposed merger (Merger Agreement dated August 16, 2026).
- Proceeds will be funded into escrow and credited to Fulcrum's net cash, potentially increasing the cash dividend from the merger.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access